A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
About the study
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- * Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
- * Have venous access sufficient to allow for blood sampling
- * Are able to swallow oral medication
- * Agree to skin biopsies
EXCLUSION CRITERIA
Exclusion Criteria:
- * Have any other skin conditions, excluding plaque psoriasis
- * Have a current or recent acute, active infection
- * Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
- * Are lactating or breastfeeding women
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Plaque Psoriasis
Age (in years)
18 - 75
Phase
PHASE2
Participants Needed
75
Est. Completion Date
Jul 31, 2025
Treatment Type
INTERVENTIONAL
Sponsor
Eli Lilly and Company
ClinicalTrials.gov NCT Identifier
NCT06176768
Study Number
J4H-MC-FVAA
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?